Angiokeratomas of Fabry successfully treated with intense pulsed light

References

• Desnick R. J., Ioannou Y. A., Eng C. M. Alpha‐galactosidase A deficiency: Fabry disease. The metabolic and molecular bases of inherited disease, C. R Scriver, A. L Beaudet, W. S Sly, D Valle, B Childs, K. W Kinzler. McGraw‐Hill, New York 2001; 3: 3733–74, 8th ed.
   Google Scholar
• Germain D. P. Genetics of Fabry disease: Diagnostic and therapeutic implications. Presse Med 2007; 36((Spec No. 1))1S14–19
   Google Scholar
• Meikle P. J., Hopwood J. J., Clague A. E., Carey W. F. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249–54
   PubMed Web of Science ®Google Scholar
• Møller A. T., Jensen T. S. Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol 2007; 3: 95–106
   Google Scholar
• Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., et al. High incidence of later‐onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31–40
   PubMed Web of Science ®Google Scholar
• Desnick R. J., Brady R., Barranger J., Collins A. J., Germain D. P., Goldman M., et al. Fabry disease, an under‐recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338–46
   PubMed Web of Science ®Google Scholar
• Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syphilol 1898; 43: 187–201
   Google Scholar
• Anderson W. A case of angeio‐keratoma. Br J Dermatol 1898; 10: 113–17
   Google Scholar
• Eng C. M., Fletcher J., Wilcox W. R., Waldek S., Scott C. R., Sillence D. O., et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30: 1864–92
   Google Scholar
• Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., et al. Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236–42
   PubMed Web of Science ®Google Scholar
• Wang R. Y., Lelis A., Mirocha J., Wilcox W. R. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007; 9: 34–45
   PubMed Web of Science ®Google Scholar
• Wilcox W. R., Oliveira J. P., Hopkin R. J., Ortiz A., Banikazemi M., Feldt‐Rasmussen U., et al. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab 2008; 93: 112–28
   PubMed Web of Science ®Google Scholar
• Deegan P. B., Baehner A. F., Barba Romero M‐Á., Hughes D. A., Kampmann C., Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006; 43: 347–52
   PubMed Web of Science ®Google Scholar
• Mehta A. New developments in the management of Anderson‐Fabry disease. Q J Med 2002; 95: 647–53
   Google Scholar
• Clarke J. T. R. Narrative review: Fabry disease. Ann Intern Med 2007; 146: 425–33
   PubMed Web of Science ®Google Scholar
• Ramaswami U., Whybra C., Parini R., Pintos‐Morell G., Mehta A., Sunder‐Plassmann G., et al. Clinical manifestations of Fabry disease in children: Data from the Fabry Outcome Survey. Acta Paediatr 2006; 95: 86–92
   PubMedGoogle Scholar
• Orteu C. H., Jansen T., Lidove O., Jaussaud R., Hughes D. A., Pintos‐Morell G., et al. Fabry disease and the skin: Data from FOS, the Fabry outcome survey. Br J Dermatol 2007; 157: 331–7
   PubMed Web of Science ®Google Scholar
• Larralde M., Boggio P., Amartino H., Chamoles N. Fabry disease: A study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. Arch Dermatol 2004; 140: 1440–6
   Google Scholar
• Möhrenschlager M., Braun‐Falco M., Ring J., Abeck D. Fabry disease: Recognition and management of cutaneous manifestations. Am J Clin Dermatol 2003; 4: 189–96
   Google Scholar
• Mahé E., Hadj‐Rabia S., Chauveau D., de Prost Y. Maladie de Fabry: Place du dermatologue et progrès thérapeutiques. Ann Dermatol Venereol 2005; 132: 171–6
   Google Scholar
• Eng C. M., Germain D. P., Banikazemi M., Warnock D. G., Wanner C., Hopkin R. J., et al. Fabry disease: Guidelines for the evaluation and management of multi‐organ system involvement. Genet Med 2006; 8: 539–48
   PubMed Web of Science ®Google Scholar
• Lidove O., Bekri S., Goizet C., Khau Van Kien A., Aractingi S., Knebelmann B., et al. Fabry disease: Proposed guidelines from a French expert group for its diagnosis, treatment and follow‐up. Presse Med 2007; 36: 1084–97
   Google Scholar
• Schiffmann R., Kopp J. B., Austin H. A., 3rd, Sabnis S., Moore D. F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001; 285: 2743–9
   PubMed Web of Science ®Google Scholar
• Eng C. M., Guffon N., Wilcox W. R., Germain D. P., Lee P., Waldek S., et al. Safety and efficacy of recombinant human alpha‐galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9–16
   PubMed Web of Science ®Google Scholar
• Barbey F., Hayoz D., Widmer U., Burnier M. Efficacy of enzyme replacement therapy in Fabry disease. Curr Med Chem 2004; 2: 277–86
   Google Scholar
• Lidove O., Joly D., Barbey F., Bekri S., Alexandra J. F., Peigne V., et al. Clinical results of enzyme replacement therapy in Fabry disease: A comprehensive review of literature. Int J Clin Pract 2007; 61: 293–302
   PubMed Web of Science ®Google Scholar
• Cochat P., Liutkus A., Dubourg L., Levade T. Current management of Fabry disease. Nephrol Ther 2006; 2((suppl 2))S167–71
   Google Scholar
• Brady R. O. Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res 2006; 9: 237–44
   PubMed Web of Science ®Google Scholar
• Torezan L., Osório N. Laser em Dermatologia: Princípios físicos, tipos e indicações. An Bras Dermatol 1999; 74: 13–20
   Google Scholar